Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
2018 · New England Journal of Medicine · 2,782 citations
https://doi.org/10.1056/nejmoa1716153
M
Mitsuharu Ueda
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
713
Papers
13.8K
Citations
54
h-index
231
i10-index
Mitsuharu Ueda is an academic researcher from Kumamoto University. The author has contributed to research in topics: Amyloidosis: Diagnosis, Treatment, Outcomes & Parathyroid Disorders and Treatments & Alzheimer's disease research and treatments. The author has an h-index of 54, co-authored 607 publications.
ORCID: 0000-0002-6814-0582Papers by this author
worksDiagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm
2018 · Orphanet Journal of Rare Diseases · 146 citations
https://doi.org/10.1186/s13023-017-0726-x
Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
2019 · Journal of Neurology · 58 citations
https://doi.org/10.1007/s00415-019-09602-8
Novel Antibody for the Treatment of Transthyretin Amyloidosis
2016 · Journal of Biological Chemistry · 48 citations
https://doi.org/10.1074/jbc.m116.738138
DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells
2022 · Leukemia · 42 citations
https://doi.org/10.1038/s41375-022-01708-9
Deep learning-based reconstruction can improve the image quality of low radiation dose head CT
2023 · European Radiology · 34 citations
https://doi.org/10.1007/s00330-023-09559-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat